«It
performed so well in the
preclinical model, we determined that to boost its effects further was essentially impossible,» said Orme, also a co-founder of CSU's Mycobacteria Research Laboratories.
and affinity of antibody ACI - 5400 were characterized by a panel of methods: (i) measuring the selectivity for a specific phospho - Tau epitope known to be associated with tauopathy, (ii)
performing a combination of peptide and protein binding assays, (iii) staining of brain sections from mouse
preclinical tauopathy
models and from human subjects representing six different tauopathies, and (iv) evaluating the selective binding to pathological epitopes on extracts from tauopathy brains in non-denaturing sandwich assays.